Curated News
By: NewsRamp Editorial Staff
September 18, 2026
VERAXA Appoints Raju Willener as CFO to Drive Oncology Pipeline
TLDR
- VERAXA Biotech named Raju Willener CFO, adding 30 years of capital-markets expertise to advance its BiTAC oncology pipeline and gain a financial edge.
- VERAXA Biotech appointed Raju Willener as CFO, effective immediately, to oversee financial strategy as the company advances its BiTAC platform and antibody-drug conjugate pipeline.
- VERAXA Biotech's new CFO Raju Willener will help drive novel cancer therapies forward, potentially improving outcomes for patients and making tomorrow better than today.
- Did you know VERAXA Biotech just appointed a CFO with 30 years of global finance experience while developing cutting-edge cancer therapies like BiTAC-ADCs.
Impact - Why it Matters
The appointment of Raju Willener as CFO brings decades of capital markets expertise to VERAXA at a critical juncture. As the company advances its BiTAC platform, including promising antibody-drug conjugates and T-cell engagers, strong financial leadership is essential to secure funding, manage partnerships, and navigate regulatory pathways. For patients and investors, this could mean faster development of innovative cancer therapies that address unmet needs. Willener’s experience in international finance and corporate development will help VERAXA scale efficiently, potentially accelerating the delivery of next-generation treatments. In the competitive biotech landscape, such strategic hires often signal a company’s readiness to transition from research to commercialization, making this news a positive indicator for stakeholders.
Summary
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has named Raju Willener as its new chief financial officer, effective immediately. Willener brings over 30 years of international experience in investment banking, corporate finance, asset management, and capital markets across the United States, Europe, and Asia. He will report directly to CEO and co-founder Christoph Antz, Ph.D. The appointment comes at a pivotal time as VERAXA advances its proprietary BiTAC platform and a pipeline focused on antibody-drug conjugates (ADCs) and T-cell engagers. The company has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform, underscoring its potential to deliver next-generation oncology treatments.
Willener’s extensive background includes a prior role as director of corporate development at Exentis Group AG, where he played a key role in strategic initiatives. His expertise in capital markets and corporate finance is expected to be instrumental as VERAXA navigates the complex landscape of biotechnology financing and drug development. The company’s focus on innovative cancer therapies positions it at the forefront of immuno-oncology, and Willener’s leadership will be crucial in driving financial strategy and supporting the advancement of its promising pipeline.
Investors and industry observers can find more details about VERAXA’s progress and this strategic hire by visiting the company’s newsroom at https://ibn.fm/VRXA, as highlighted in the original announcement distributed via NEWMEDIAWIRE. For a deeper dive into the news, read the full release on Read More. As VERAXA continues to develop its BiTAC-ADC platform and other novel therapies, the addition of a seasoned financial executive like Willener signals a strong commitment to operational excellence and long-term growth.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, VERAXA Appoints Raju Willener as CFO to Drive Oncology Pipeline
